GLD vs XBI

SPDR Gold Shares vs SPDR S&P Biotech ETF

Quick take
  • • XBI has the lower expense ratio at 0.35% vs 0.40% for GLD.
  • • XBI pays a higher dividend yield (0.35%).

Side-by-side metrics

MetricGLDXBI
Expense ratio
Annual fee. Lower is better.
0.40%0.35%
Dividend yield
Trailing 12-month yield.
0.00%0.35%
AUM
Assets under management — bigger funds are typically more liquid.
$131.01B$10.92B
YTD return
-4.23%28.80%
1-year return
——
3-year return
Annualized.
——
5-year return
Annualized.
——
10-year return
Annualized.
——
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
0.471.01
P/E ratio
——
Last price
$365.94$156.41
Inception
——
Issuer
State StreetState Street

GLD top holdings

Holdings data unavailable for GLD.

XBI top holdings

Top holdings · XBI
MRNAModerna Inc2.37%
NTRANatera Inc1.82%
HALOHalozyme Therapeutics Inc1.77%
TWSTTwist Bioscience Corp1.77%
BIIBBiogen Inc1.75%
AMGNAmgen Inc1.73%
EXELExelixis Inc1.73%
UTHRUnited Therapeutics Corp1.72%
ABBVAbbVie Inc1.71%
GILDGilead Sciences Inc1.70%
Sector breakdown · XBI
Financial Services0.6%
Healthcare99.3%

About GLD

GLD (SPDR Gold Shares) is Physically backed gold ETF. Managed by State Street, the fund carries $131.0B in assets under management, an expense ratio of 0.40%.

About XBI

XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.